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Abstract
Introduction
Stated preference studies for cancer screening programs
are used to understand how the programs can be improved
to maximize usage. Our objectives were to conduct a sys-
tematic review of stated preference studies for cancer
screening, identify gaps in the literature, and determine
which types of research should be conducted in the future.
Methods
We considered all studies in the PubMed database
through May 2005 that measured utility-based stated pref-
erences for cancer screening using contingent valuation or
conjoint analysis. We abstracted data on 1) study charac-
teristics and 2) study results and policy implications.
Results
We found eight (of 84 identified) preference studies for
cancer screening. The most commonly studied cancer was
breast cancer, and the most commonly used method was
contingent valuation. We found no studies for prostate can-
cer or physician preferences. Studies demonstrated that
although individuals are able to state their preferences for
cancer screening, they do not weigh test benefits and
harms, and a significant percentage would choose to have
no screening at all. Several studies found that test accura-
cy and reduction in mortality risk were important for
determining preferences.
Conclusion
Few studies of cancer screening preferences exist. The
available studies examine only a few types of cancer and do
not explore practice and policy implications in depth. The
results of this review will be useful in identifying the focus
of future research, identifying which screening methods
may be more preferred to increase use of the programs,
and developing interventions and policies that could facili-
tate informed and shared decision making for screening.
Introduction
In the United States, several types of cancer screening
have been recommended, and increasing the number of
individuals who receive recommended cancer screenings is
a health priority. Therefore, it is important to understand
individual screening preferences and how the preferences
can be used to develop future programs and policies. The
objectives of this study were as follows:
1. Conduct a systematic review of the PubMed database
for stated preference studies on cancer screening by
using contingent valuation or conjoint analysis
approaches to identify the numbers and types of pub-
lished studies
2. Identify gaps in the literature and assess which types
of research should be conducted in the future to better
assess the influence of individual preferences on can-
cer screening decisions, clinical practice, and health
policy.
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Previous studies have found that patient preferences for
health care interventions can have a large impact on their
willingness to use services and on the resulting outcomes
(1). Understanding preferences is also important because of
the increasing emphasis on involving patients in decisions
about their care. However, measurement, or valuation, of
individuals’ preferences for health care interventions such
as cancer screening programs is a significant challenge for
health care researchers because this type of information is
typically obtained from surveys. The most commonly used
approaches to valuation are attitude surveys, which ask
respondents to rate their opinion about individual health
care services, and utility-based preference surveys, which
use more complex approaches that are based on economic
theory. Although the terms attitudes and preferences are
occasionally used interchangeably, the term preferences in
this article refers to preferences based on economic theory
— patients have preferences for health care, and they seek
to maximize usefulness within the constraints of a budget.
Understanding preferences, rather than simply attitudes,
is particularly important for understanding the use of can-
cer screening because preference studies provide insights
into how individuals weigh harms and benefits of tests and
quantify preferences into dollars.
This review focuses on stated preference studies — or
studies of cancer screening preferences that were meas-
ured using a theoretically based, economic approach and
that used contingent valuation or conjoint analysis
approaches. To our knowledge, no review of these types of
preference studies of cancer screening has been done. The
results will be useful in identifying areas for future
research, identifying which screening methods may be pre-
ferred to increase usage, and developing interventions and
policies that could facilitate informed and shared decision
making about screening.
Methods
Definition of preference study
Several approaches are available for measuring prefer-
ences, and much confusion in the literature exists about
the terms used to describe different types of studies. In this
study, we limited our analyses to utility-based preference
studies using contingent valuation surveys (also called
willingness-to-pay surveys) or conjoint analysis surveys
(also called choice format stated preferences or discrete
choice experiments). Thus, we did not include attitude
studies or preference studies used to develop health-state
utility weights for use in quality-adjusted life years or
other utility approaches. Contingent valuation and con-
joint analysis approaches are often the most relevant to
cancer screening and thus are the focus of our study. These
methods measure the value of screening programs and the
process of care as well as outcomes, not just health states.
Furthermore, the use of these methods is increasing
because of their strengths in realistically measuring choic-
es and the harms and benefits of screening.
Contingent valuation studies use questionnaires to esti-
mate the willingness of respondents to pay for projects or
programs, typically public programs for which there is no
defined market. For example, a contingent valuation of
preferences for colorectal cancer screening would describe
a possible screening program and ask individuals how
much they would be willing to pay for such a program.
Conjoint analysis studies involve comparing hypothetical
scenarios by ranking, rating, or choosing scenarios. For
example, respondents may be asked to choose from test A
and test B after each test is described by using a combina-
tion of attributes. A conjoint analysis of preferences for col-
orectal cancer screening might describe different testing
methods in terms of process, accuracy, and cost. Examples
of each type of survey are included in Appendices A and B.
Inclusion and exclusion criteria
We included all studies that measured stated patient
preferences for cancer screening using conjoint analysis or
contingent valuation. Studies that used simple rating
scales to measure attitudes or studies that measured util-
ity weights using time trade-off, standard gamble, or rat-
ing scales were excluded. A study was considered to be a
cancer screening study if it examined a cancer screening
program, test, or method. Studies that focused primarily
on methodology of preference measurement, examined
preferences for treatment, or focused on diagnosing disease
characteristics (such as screening known cancers for genet-
ic mutations) were excluded.
Data source and search strategy
We searched the PubMed (Medline) database for studies
that measured patient preferences for cancer screening,
using several search strategies to identify all potentially
relevant studies. Our search included all English articles
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through May 2005 with no limitations on start date. To
identify search terms, we first reviewed the index for sev-
eral known studies of quantitative preference measure-
ment (1-4). Preliminary search results suggested that
study indexing is not standardized, possibly because nei-
ther terms for preference measurement (e.g., conjoint
analysis) nor the term preference are associated with a
unique medical subject heading (MeSH) term in PubMed.
Therefore, we combined MeSHs for the four key compo-
nents of interest. The search strategy combined the follow-
ing terms by using Boolean operators — OR within the
four categories and AND across the categories:
1. Cancer terms. We used the MeSH term neoplasm OR
the keyword cancer.
2. Screening terms. We used the MeSH terms mass
screening OR mass screening/economics and keywords
cancer OR screening.
3. Preference terms. No MeSH term for preferences
exists. Thus, we used a combination of the MeSH terms
patient satisfaction/economics OR patient satisfac-
tion/statistics & numerical data OR consumer satisfac-
tion/economics OR consumer satisfaction/statistics &
numerical data OR health knowledge, attitudes, prac-
tice as well as the keywords preference(s) OR attitudes.
4. Quantitative methods. We used one MeSH term,
choice behavior, and keywords conjoint analysis OR
contingent valuation OR stated preference OR discrete
choice OR willingness to pay to capture the quantita-
tive methods used to measure preferences.
Study selection and coding
Two authors (SVB and KAP) independently reviewed
titles and abstracts, and all potential articles were
obtained for additional review. The two authors also con-
ducted all data abstraction and reached consensus through
discussion about any disagreement. We abstracted two
types of information: 1) study descriptions (cancer site,
method used, objectives, and population), and 2) study
results and policy implications.
Results
We found eight stated preference studies for cancer
screening (of 84 identified) (Figure). Three fourths of the
studies were excluded based on the abstract or title either
because they were not stated preference studies (n = 24) or
because they were not relevant to cancer screening (n =
37). Fifteen of the remaining 23 citations were subse-
quently excluded after a full review: six were not stated
preference studies and one was not relevant to cancer
screening. We also excluded eight studies, even though
they were cancer screening preference studies, because
they focused on methodological issues.
Table 1 describes the included studies (4-11). The most
commonly studied types of cancer were breast cancer (n =
4) and colorectal cancer (n = 3). We found no preference
studies for prostate cancer screening, even though prostate
cancer is the most common cancer among men, and pref-
erences are particularly important because no consensus
exists on the appropriateness of prostate cancer screening.
The most commonly used method to assess preference was
contingent valuation to determine willingness to pay (n =
5). Most studies administered surveys to a general popula-
tion (n = 6).
Several policy implications emerged from the study
results (Table 2). Studies demonstrated that individuals
were able to provide meaningful responses and state their
preferences for cancer screening, although many respon-
dents did not consider the potential harms of a particular
screening test, and a significant percentage would not
choose any type of screening (4,8). Several studies found
that test accuracy and a reduction in mortality risk were
important for determining preferences (4,7,9). Researchers
generally noted that preference studies could provide use-
ful information for clinicians and policymakers in deter-
mining the net benefits of screening programs and which
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Figure. Flow chart of PubMed database search strategy and results. 
VOLUME 3: NO. 3
JULY 2006
screening types may be most preferred, but none of the
studies explored clinical or policy implications in detail.
Several studies showed that test accuracy plays an
important role in preference for screening (4,7,9).
Furthermore, our colorectal cancer screening studies have
found that sensitivity (i.e., the ability of the test to identi-
fy those with cancer) is more highly valued than specifici-
ty (i.e., the ability of the test to correctly identify those
without cancer) (12). The study by Salkeld et al (8) high-
lights another important finding: many people may prefer
no screening at all, thus the currently available methods of
screening may actually provide disutility to some individu-
als (i.e., they may think the tests cause more harm than
good).
Discussion
Only a few preference studies for cancer screening have
been published; they assess few types of cancer and have a
limited range of questions. We were surprised that we did
not identify any studies of physicians’ predictions about
their patients’ preferences. Physician recommendations for
screening have consistently been found to be strong pre-
dictors of screening usage, so it is important to understand
how well physicians’ views of preferences actually reflect
patients’ preferences. We found in our ongoing study of col-
orectal cancer screening that physicians’ views of patients’
preferences were not congruent with what patients report-
ed they preferred (12). In particular, physicians were much
more likely to predict that patients would prefer no screen-
ing when the patients actually preferred screening, which
may explain why some physicians do not always offer
screening to their patients.
Our review suggests that although preference studies
can provide useful findings that can improve our under-
standing of cancer screening, more research needs to be
completed. We found that test accuracy plays a role in
screening preference. The preference for sensitivity over
specificity suggests that individuals tend to prefer false-
positive results over false-negative results. This may help
explain the willingness of individuals to receive complete-
body computed tomography scans and for women aged 40
to 50 years to undergo mammography screenings, despite
the high rate of false-positives for such procedures.
Schiffner et al (9) confirm that patients may not under-
stand the potential drawbacks of having false-positive
results. This finding by Salkeld et al (8) that many people
prefer no screening is important from a methodological
perspective because it suggests that preference surveys
should consider measuring not only preferences for screen-
ing but also preferences for no screening.
Our findings also suggest that it may be necessary to
develop new methods of screening that better address
patient preferences. Although we recognize the ongoing
debate about whether the goal of preventive public health
programs is to maximize participation in screening or max-
imize the usefulness of the screening, our study did not
address these issues. Regardless, preference information
can be useful for meeting either goal.
None of the studies explored in detail the implications of
their results for clinical practice and health policy. This
research gap is surprising given the current emphasis on
more patient participation and shared, or informed, deci-
sion making between patients and providers. For example,
some guidelines for mammography screening for women
aged 40 to 50 years recommend that screening decisions be
based on preferences and shared decision making. In gen-
eral, research on informed decision making and decision
aids is based on attitude data rather than true preference
data, although preference data could provide additional
insight into what patients want and how to elicit prefer-
ences for use in decision making. Thus, one key area for
future research is the development of mechanisms that
enable the use of preference data. During the development
of such mechanisms, researchers will need to consider how
to simplify the often time-consuming surveys used to
measure preferences and develop efficient ways to use
preference data in clinical practice. Similarly, preferences
need to be incorporated into health policies. For example,
our finding that many people would prefer colonoscopy
over other forms of colorectal cancer screening provides
important information, because many private insurers and
government health systems do not currently provide cov-
erage for colonoscopies (13).
Our study has limitations. Our literature search may not
have identified potentially relevant studies that have not
been indexed in PubMed or published in English. In addi-
tion, because the studies we found had varying methods
(e.g., contingent valuation, conjoint analysis), research
questions, and cancer types, we were unable to conduct a
quantitative analysis such as a meta-analysis. We exclud-
ed other types of utility studies because they were not as
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relevant to this review, but future researchers could exam-
ine these studies.
Although we identified only a few studies of cancer
screening preferences, the published studies have provided
some useful results. More research is needed to identify
preferences to help clinicians and decision makers improve
screening programs.
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Tables
Table 1. Reviewed Studies for Stated Preferences for Cancer Screening (N = 8)
Table 2. Summary of Primary Results and Policy Implications of Reviewed Studies for Stated Preferences for Cancer
Screening (N = 8)
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Frew et al (5)
Gyrd-Hansen (6)
Gyrd-Hansen and
Sogaard  (4)
Liang et al (7)
Salkeld et al (8)
Schiffner et al (9)
Wagner et al (10)
Wordsworth et al (11)
Colorectal
Breast
Breast, colorectal
Breast
Colorectal
Skin
Breast
Cervical
Contingent valuation
Conjoint analysis
Conjoint analysis
Contingent valuation
Conjoint analysis, con-
tingent valuation
Contingent valuation
Contingent valuation
Contingent valuation
To examine willingness to pay for fecal
occult blood testing and flexible sigmoi-
doscopy
To assess all costs incurred by and effects of
introducing mammography screening
To determine population preferences for
cancer screening programs
To assess acceptability of a new noninvasive
breast cancer diagnostic test intended to
triage women in need of biopsy
To elicit preferences for colorectal cancer
screening by fecal occult blood testing
To determine the difference between
patients’ confidence (as measured by will-
ingness to pay) in current diagnostic meth-
ods and a diagnostic method promising
100% accuracy
To examine willingness to pay for mammog-
raphy among five ethnic groups
To assess the value of cervical smear
(Papanicolaou) testing
General population (N = 2000)
General population (N = 207)
General population (N = 750)
Patients (N = 43)
General population (N = 301)
Patients (N = 210)
General population (N = 1465)
General population (N = 2000)
Population and 
Study Cancer Type Preference Method Objective Sample Size
Frew et al (5)
Gyrd-Hansen (6)
Gyrd-Hansen and Sogaard (4)
Willingness to pay for flexible sigmoidoscopy was similar to
likely resource costs of screening for sigmoidoscopy and
fecal occult blood testing.
The study involved a cost-benefit analysis using preference
data and found that net benefits are maximized when
mammography screening is targeted biennially to women
aged 50-74 years.
Preferences for colorectal and breast cancer screening
were primarily explained by positive utility associated with
reducing mortality risk and disutility from out-of-pocket
expenses.
The study helps establish extent to which a new technolo-
gy would be valued by the public.
Preference studies can be used to identify inferior programs.
It is important to identify the relative importance of pro-
gram attributes to identify and exclude programs that con-
sume more resources and provide less utility.
Study Primary Results Policy Implications
(Continued on next page)
(Adapted from Salkeld et al [8].)
Interviewees were provided with the following information about
colorectal cancer screening:
• They were given background information on the screening (e.g.,
diagnosis in absence of screening, information about fecal occult
blood testing, opportunity costs of a screening program).
• They were asked to imagine that they had been invited by their local
doctor (general practitioner) to have this test for free.
• They were given a description of two identical colorectal cancer bien-
nial screening programs for a population of 10,000 men and
women aged 50 to 69 years.
• They were told that the programs were identical except for three
characteristics for which standardized descriptions were provided:
benefits (number of colorectal cancer deaths prevented), harms
(number of colonoscopies resulting from a false-positive fecal occult
blood test result), and notification policy (whether they would be
notified of a negative test result).
• They were given a description of the colonoscopy procedure and a
statement on the rate of complications arising from colonoscopies
performed on the screened population.
Interviewees were then given a scenario and a question, such as:
“Could you please compare the two programs, and tell me whether
you would prefer Program A or Program B or whether you would prefer
not to have the screening test?” An example follows:
Sample Scenario (per 10,000 Men and Women Screened
Over 10 Years)
Number of colorectal cancer deaths prevented 8 14
Number of unnecessary colonoscopies resulting 2400 8400
from false-negative tests
Notification of negative test result Yes Yes
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Table 2. (continued) Summary of Primary Results and Policy Implications of Reviewed Studies for Stated Preferences for
Cancer Screening (N = 8)
Liang et al (7)
Salkeld et al (8)
Schiffner et al (9)
Wagner et al (10)
Wordsworth et al (11)
Women would find noninvasive triage tests for breast can-
cer acceptable or preferable to biopsy if they were equally
accurate.
Three characteristics of colorectal cancer screening varied:
benefits (deaths prevented), harms (unnecessary
colonoscopy), notification policy (test result).
12% always preferred no screening.
32% would always choose the screening method that pro-
vides the most survival benefits (i.e., harms of screening
were irrelevant).
Patients underestimated the actual test accuracy for malig-
nant melanoma.
A distinct gap was found between patients’ level of confi-
dence in current methods and a hypothetical tool with
100% safety.
Willingness to pay differed by race and ethnicity.
The value women place on having a Papanicolaou test is
more than the test's actual costs to UK National Health
Service for providing the service.
Study Primary Results Policy Implications
New technologies should focus on decreasing discomfort
as well as increasing test accuracy.
In any future national screening program, careful consider-
ation should be given to selection of screening tests based
on the community’s assessment of benefits, harms, costs,
and other characteristics.
Accuracy is highly valued but not well understood by
patients.
Better information about diagnostic accuracy is necessary
to increase patients’ knowledge of and confidence in
tests.
Preference studies that do not account for ethnic differ-
ences may be overstating net benefits to society.
Willingness-to-pay information can be useful for policy
makers.
Characteristic Program A Program B
Appendices
Appendix A. Conjoint Analysis Example
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Question: Which would you prefer? Program A, Program B, or no
screening?
Appendix B. Willingness-to-Pay Example
(From Corso et al [14])
“I’d like to ask you a few questions about food safety.”
(Interviewee is given one of two scenarios.)
Prevention scenario: “Imagine that you are planning a trip to a
foreign country where for every 100,000 people visiting, 400 peo-
ple contract a virus from eating contaminated food. If you get the
virus, the only symptom is a slight yellowing of the skin for 2 or 3
days. The virus causes no other discomfort and does not interfere
with any of your activities. However, studies have shown that for
every 100 people who get the virus, one will die. Further, there is
no treatment at this time. Fortunately, there is a U.S. medication
available that will protect you from getting the virus in the first
place, no matter what foods you eat while traveling. This medica-
tion has NO side effects. Tests have shown that this preventive
medicine will decrease your risk of getting the virus by 50%. Thus,
your overall chances of dying from this illness can be reduced from
4 in 100,000 to 2 in 100,000 if you take the preventive medi-
cine.”
Treatment scenario: “Imagine that while traveling in a foreign
country you notice that your skin has been slightly yellow for 2 or 3
days. While you experience no other discomfort and have been
able to conduct your normal activities, you decide to visit a local
clinic run by U.S. doctors. The doctors tell you that you have con-
tracted a virus, probably from eating contaminated food, where for
every 100,000 people who have the virus, 4 will die. Fortunately
there is a U.S. medication available at the clinic. This medication
has NO side effects. Tests have shown that this medication will
reduce your chance of dying by 50%. Thus your overall chance of
dying from this virus can be reduced from 4 in 100,000 to 2 in
100,000.”
(Interviewee is then asked the following:)
“Would you consider taking this medication?”
<IF NO>“What is the main reason you would not be willing  to
take the medication?”
<IF YES>“Now assume you would have to pay some money to
get this medication — insurance would not cover it. Considering
your current income and other household expenses, would you
pay:
<$50, $100, $200, $400>
for this medication?”
<IF YES>“Would you buy this medication if the out-of-pocket cost
was:
<$100, $200, $400, $800>?”
<IF NO>“Would you buy this medication if the out-of-pocket cost
was:
<$20, $50, $100, $200>”
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